Improving hospital outpatient visits for nerve tumour patients
Part of Brain & nervous system, Cancer, Ear, nose & throat, Eyes & vision, Genetic & congenital, Mental health clinical trials.
This study asks how hospital outpatient departments can be improved for people with nerve tumour conditions. It gathers feedback from patients, carers, and staff to make care better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can take part if you are 16 or older.
- You must be a patient, a carer or relative of a patient, or a staff member involved in nerve tumour care at Guy's and St Thomas' NHS Foundation Trust.
- Patients should attend outpatient appointments for nerve tumour predisposition conditions.
- People with sensory challenges are especially welcome.
- You need to be able to give informed consent to take part.
- Temporary staff who have worked less than one shift cannot take part.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at new medicines for people with NF2-related schwannomatosis (NF2-SWN), a condition that causes tumors on nerves. It first tracks the natural course of the disease and may later test experimental drugs to help shrink or control tumors.
This study talks with people who have NF1 (and caregivers of children with NF1) about how visible tumors affect them. The goal is to create questionnaires that measure these concerns, which could lead to better support and treatments.
This study monitors people with neurofibromatosis type 1 (NF1) over time to watch for signs that their nerve tumors might turn into cancer. It helps researchers learn which tumors are more likely to change and may lead to better care.
This study checks whether patient surveys (questionnaires) can reliably measure symptoms and pain in people with NF1 who have plexiform neurofibromas. It helps create better tools for tracking how you feel and how treatments may affect quality of life.
This trial tests a new medicine called PRG-N-01 for people with neurofibromatosis type 2 (NF2), a condition that causes tumors on nerves. The study aims to find the best dose and see if the medicine can shrink tumors or improve symptoms like hearing loss or pain, especially for those who cannot have surgery.
This study follows children and teens with certain nerve-cell tumors (like neuroblastoma) that involve the spinal canal. It collects information on how these tumors behave and how treatments and outcomes may differ, aiming to improve care over the long term.
Hear when a new Neurofibromatosis Type 1 (NF1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.